Literature DB >> 18043131

Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents.

Shuraila F Zerp1, Stefan R Vink, Gerald A Ruiter, Pieter Koolwijk, Erna Peters, Arnold H van der Luit, Daphne de Jong, Marianne Budde, Harry Bartelink, Wim J van Blitterswijk, Marcel Verheij.   

Abstract

Synthetic alkylphospholipids (APLs), such as edelfosine, miltefosine and perifosine, constitute a new class of antineoplastic compounds with various clinical applications. Here we have evaluated the antiangiogenic properties of APLs. The sensitivity of three types of vascular endothelial cells (ECs) (bovine aortic ECs, human umbilical vein ECs and human microvascular ECs) to APL-induced apoptosis was dependent on the proliferative status of these cells and correlated with the cellular drug incorporation. Although confluent, nondividing ECs failed to undergo apoptosis, proliferating ECs showed a 3-4-fold higher uptake and significant levels of apoptosis after APL treatment. These findings raised the question of whether APLs interfere with new blood vessel formation. To test the antiangiogenic properties in vitro, we studied the effect of APLs using two different experimental models. The first one tested the ability of human microvascular ECs to invade a three-dimensional human fibrin matrix and form capillary-like tubular networks. In the second model, bovine aortic ECs were grown in a collagen gel sandwich to allow tube formation. We found that all three APLs interfered with endothelial tube formation in a dose-dependent manner, with a more than 50% reduction at 25 micromol/l. Interference with the angiogenic process represents a novel mode of action of APLs and might significantly contribute to the antitumor effect of these compounds.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18043131     DOI: 10.1097/CAD.0b013e3282f16d36

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  7 in total

1.  Human TMEM30a promotes uptake of antitumor and bioactive choline phospholipids into mammalian cells.

Authors:  Rui Chen; Erin Brady; Thomas M McIntyre
Journal:  J Immunol       Date:  2011-02-02       Impact factor: 5.422

2.  In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors.

Authors:  Martin Schmidt-Hieber; Robert Dabrowski; Babette Aicher; Philipp Lohneis; Antonia Busse; Carola Tietze-Buerger; Birgit Reufi; Eckhard Thiel; Igor Wolfgang Blau
Journal:  Invest New Drugs       Date:  2011-07-13       Impact factor: 3.850

3.  Inositoylated platelet-activating factor (Ino-C2-PAF) modulates dynamic lymphocyte-endothelial cell interactions and alleviates psoriasis-like skin inflammation in two complementary mouse models.

Authors:  Susann Forkel; Margarete Schön; Annette Hildmann; Anna Claßen; Swen-Malte John; Kerstin Danker; Michael P Schön
Journal:  J Invest Dermatol       Date:  2014-04-08       Impact factor: 8.551

4.  In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.

Authors:  Martin Schmidt-Hieber; Robert Dabrowski; Andreas Weimann; Babette Aicher; Philipp Lohneis; Antonia Busse; Eckhard Thiel; Igor W Blau
Journal:  Invest New Drugs       Date:  2010-11-16       Impact factor: 3.850

5.  Influence of cancerostatic perifosine on membrane fluidity of liposomes and different cell lines as measured by electron paramagnetic resonance.

Authors:  Rok Podlipec; Tilen Koklic; Janez Strancar; Janez Mravljak; Marjeta Sentjurc
Journal:  Croat Med J       Date:  2012-12       Impact factor: 1.351

6.  Exogenous ether lipids predominantly target mitochondria.

Authors:  Lars Kuerschner; Doris Richter; Hans Kristian Hannibal-Bach; Anne Gaebler; Andrej Shevchenko; Christer S Ejsing; Christoph Thiele
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

7.  The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response.

Authors:  Pierre Abramowski; Benjamin Otto; Roland Martin
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.